Blog

News

404

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions
Commentary on Protein-Protein and Protein-Peptide Interactions, peptidomimetics and related topics in drug discovery.

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced a 1.5 billion yen ($10.3M) fundraise. Funds will be used to refine PRISM’s proprietary PepMetics® chemistry platform, expand biology and screening capabilities and advance internal pipeline of PPI inhibitors. Read Full Press...

PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical

TOKYO, Japan, 31 May 2023: – PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced a milestone achievement of a clinical development conducted by Ohara Pharmaceutical Co., Ltd., a Japanese pharmaceutical company that discovers and develops orphan drugs and generic drugs, based on their licensing...

New study by PRISM Biolab demonstrates rational design of small molecule inhibitors of CTLA-4 and B7-1 protein-protein interaction utilizing only a sequence of a binding peptide

The paper published in the special issue of Pharmaceuticals journal dedicated to “Small Molecules Targeting Protein-Protein Interactions (PPIs): Current Strategies for the Development of New Drugs” presents a new method to generate small-molecules PPI inhibitors using only a sequence of a binding peptide. Potent and active PPI inhibitor peptides can be readily generated by various...

Pharma Intelligence Award Japan 2022 Commemorative Webinar “PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm”

PRISM BioLab’s proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein interactions by small molecules with a unique peptide-mimicking backbone, potentially creating a new drug discovery paradigm. In this webinar, Dai Takehara, President of PRISM BioLab, will introduce the PepMetics® technology and share his experiences in managing a biotech startup,...

Scroll to top
en_USEnglish